A Mechanism-Based PK/PD Model for Hematological Toxicities Induced by Antibody-Drug Conjugates

Antibody-drug conjugates (ADCs) are complex drug platforms composed of monoclonal antibodies (mAbs) conjugated to potent cytotoxic drugs (payloads) via chemical linkers, enabling selective payload delivery to neoplastic cells, resulting in improved efficacy and reduced toxicity. Brentuximab vedotin (Adcetris®, SGN-35) and adotrastuzumab emtansine (Kadcyla®, T-DM1) are the two FDA-approved and commercially available ADCs, and both drugs exhibit ADC-related thrombocytopenia and neutropenia. A pharmacokinetic/pharmacodynamic (PK/PD) model for ADCs was developed to identify the analyte from each ADC that is most associated with the observed hematopoietic toxicities and to determine the role of the apparent in vivo payload release rate on the severity of thrombocytopenia and neutropenia. Murine xenograft experiments and data from literature were combined, and the PK of both ADCs and their analytes were described with two-compartment models, with linear elimination and first-order payload release rate constants (krel). ADC-associated hematotoxicities were captured with a previously published PD model for myelosuppression driven by various analytes. ADC half-lives were about 5 days, and krel values were 0.46 (T-DM1) and 0.12 h−1 (SGN-35). The lifespans of platelets following T-DM1 and neutrophils following SGN-35 were 3.73 and 4.72 days. Comparison of alternate model structures suggested that mechanisms of myelosuppression are payload-driven for SGN-35 and ADC pinocytosis-dependent for T-DM1. Model simulations suggested that a 4-fold increase (T-DM1) and 70% decrease (SGN-35) in krel would improve hematotoxicity to grade 1. The proposed model successfully captured the PK and associated myelosuppression of both ADCs and might serve as a general PK/PD platform for assessing hematological toxicities to ADCs.

[1]  N. Lemoine,et al.  Expression of the c-erbB-3 protein in normal human adult and fetal tissues. , 1992, Oncogene.

[2]  Gary H Lyman,et al.  Management of chemotherapy-induced neutropenia: measuring quality, cost, and value. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

[3]  J. Barreto,et al.  Antineoplastic Agents and the Associated Myelosuppressive Effects , 2014, Journal of pharmacy practice.

[4]  H. Erickson,et al.  ADME of Antibody–Maytansinoid Conjugates , 2012, The AAPS Journal.

[5]  B. Nieswandt,et al.  Expression and Function of the Mouse Collagen Receptor Glycoprotein VI Is Strictly Dependent on Its Association with the FcRγ Chain* , 2000, The Journal of Biological Chemistry.

[6]  R. Advani,et al.  Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  H. Miyazaki,et al.  Multilineage hematopoietic recovery by a single injection of pegylated recombinant human megakaryocyte growth and development factor in myelosuppressed mice. , 1998, Blood.

[8]  Patricia A Corrigan,et al.  Ado-trastuzumab Emtansine , 2014, The Annals of pharmacotherapy.

[9]  Suzanne F. Jones,et al.  Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Howard L McLeod,et al.  A mouse-based strategy for cyclophosphamide pharmacogenomic discovery. , 2003, Journal of applied physiology.

[11]  J. W. Booth,et al.  Divergent Intracellular Sorting of FcγRIIA and FcγRIIB2* , 2010, The Journal of Biological Chemistry.

[12]  Scott E Smith,et al.  Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  L. Friberg,et al.  A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibody–Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer , 2014, The AAPS Journal.

[14]  U. Jäger,et al.  Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience. , 2012, Blood.

[15]  J. Borghans,et al.  In vivo labeling with 2H2O reveals a human neutrophil lifespan of 5.4 days. , 2010, Blood.

[16]  M. Sliwkowski,et al.  Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2–Positive Cancer , 2011, Clinical Cancer Research.

[17]  V. Roy,et al.  Thrombocytopenia in adults: A practical approach to evaluation and management. , 2006, Southern medical journal.

[18]  Yan Chen,et al.  Statistical modeling of the drug load distribution on trastuzumab emtansine (Kadcyla), a lysine-linked antibody drug conjugate. , 2014, Bioconjugate chemistry.

[19]  Mats O Karlsson,et al.  Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  P. Senter,et al.  Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates , 2014, Nature Biotechnology.

[21]  Michele Signore,et al.  Chemotherapy-induced thrombocytopenia derives from the selective death of megakaryocyte progenitors and can be rescued by stem cell factor. , 2007, Cancer research.

[22]  C. Cordon-Cardo,et al.  Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. , 1990, Oncogene.

[23]  John P Leonard,et al.  Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. , 2010, The New England journal of medicine.

[24]  R. Blum,et al.  Maytansine: a phase I study of an ansa macrolide with antitumor activity. , 1978, Cancer treatment reports.

[25]  A. Tolcher,et al.  Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. Chari Targeted cancer therapy: conferring specificity to cytotoxic drugs. , 2008, Accounts of chemical research.

[27]  A. Wahl,et al.  In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  S. Rafii,et al.  Tie2 activation contributes to hemangiogenic regeneration after myelosuppression. , 2005, Blood.

[29]  Paul Polakis,et al.  Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index , 2008, Nature Biotechnology.

[30]  J. Harrold,et al.  Semi‐mechanistic Population Pharmacokinetic Model of Multivalent Trastuzumab Emtansine in Patients with Metastatic Breast Cancer , 2012, Clinical pharmacology and therapeutics.

[31]  Heather Donaghy,et al.  Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates , 2016, mAbs.

[32]  B. Nieswandt,et al.  Expression and function of the mouse collagen receptor glycoprotein VI is strictly dependent on its association with the FcRgamma chain. , 2000, The Journal of biological chemistry.

[33]  M. Sliwkowski,et al.  Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1) , 2014, Clinical Cancer Research.

[34]  M. Sliwkowski,et al.  Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice , 2010, Journal of Pharmacokinetics and Pharmacodynamics.

[35]  M. Sliwkowski,et al.  Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer. , 2011, Clinical breast cancer.

[36]  B. Tomczuk,et al.  Current ADC Linker Chemistry , 2015, Pharmaceutical Research.

[37]  B. Curtis Drug-induced immune neutropenia/ agranulocytosis , 2014, Immunohematology.

[38]  B. Gunter,et al.  The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates , 2012, Molecular Cancer Therapeutics.

[39]  Damon L. Meyer,et al.  cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. , 2003, Blood.

[40]  H. Rugo,et al.  A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer , 2012, Cancer Chemotherapy and Pharmacology.

[41]  R. Meyboom,et al.  Drug-Induced Immune Thrombocytopenia , 2004, Drug safety.

[42]  Andrew C. Hooker,et al.  Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models , 2011, The AAPS Journal.

[43]  M. Turner,et al.  The Fc receptor γ‐chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen , 1997, The EMBO journal.

[44]  J. Italiano,et al.  High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)--mediated inhibition of platelet production. , 2012, Blood.

[45]  R. Lutz,et al.  Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. , 2006, Cancer research.

[46]  D. Benjamin,et al.  Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate , 2010, Clinical Cancer Research.

[47]  J. Doroshow,et al.  The promise of antibody-drug conjugates. , 2012, The New England journal of medicine.

[48]  S. Owen,et al.  Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry , 2015, The AAPS Journal.

[49]  A. Scott,et al.  Antibody–Drug Conjugates for Cancer Therapy , 2016, Biomedicines.

[50]  A. Tolcher,et al.  Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study , 2008, Cancer Chemotherapy and Pharmacology.

[51]  H. Rugo,et al.  Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  Dhaval K. Shah,et al.  Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin , 2012, Journal of Pharmacokinetics and Pharmacodynamics.

[53]  P. Sullivan,et al.  Successful determination of platelet lifespan in C3H mice by in vivo biotinylation. , 1996, Laboratory animal science.

[54]  L. Parker,et al.  A therapeutic trial of maytansine. , 1978, Cancer clinical trials.

[55]  E. Wright,et al.  Haemopoietic stem cells: their heterogeneity and regulation , 1997, International journal of experimental pathology.

[56]  Qiuyang Zhang,et al.  Monomethyl Auristatin E Phosphate Inhibits Human Prostate Cancer Growth , 2016, The Prostate.

[57]  R. Advani,et al.  A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies , 2011, Clinical Cancer Research.

[58]  H. Scher,et al.  Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. , 2008, Journal of Clinical Oncology.

[59]  Uma Yasothan,et al.  Brentuximab vedotin , 2012, Nature Reviews Drug Discovery.

[60]  Damon L. Meyer,et al.  Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate , 2004, Clinical Cancer Research.

[61]  Aman P. Singh,et al.  Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1) , 2016, The AAPS Journal.